N/A N=239 Prevention

Anti-mold Azole in the Prophylaxis for Invasive Fusariosis

Fusariosis · Onychomycosis

Bottom Line

View on ClinicalTrials.gov: NCT02714504 ↗

Enrolled (actual)

239

Serious AEs

0.0%

Results posted

Sep 2018

Primary outcome: Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Voriconazole or posaconazole (Drug)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Universidade Federal do Rio de Janeiro
Primary completion: Dec 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery	6; 8	—

Summary

Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with dermatologic examination. In the presence of any skin lesion in the extremities, direct exam and fungal culture will be performed. If these exams indicate the presence of Fusarium species, patients will receive anti-mold azole prophylaxis

Eligibility Criteria

Inclusion Criteria

admission for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia

Exclusion Criteria

prior documentation of invasive fusariosis or allergy to azoles

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02714504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.